Pfizer Inc. is poised to enter the migraine market with the full strength of its marketing power, raising the stakes in an already crowded and competitive commercial market. Pfizer announced a deal on 10 May to buy the migraine specialist Biohaven Pharmaceutical Holding Company Ltd. in a transaction valued at $11.6bn, gaining the oral migraine drug Nurtec ODT (rimegepant) and a nasal spray, zavegepant, pending at the US Food and Drug Administration, as well as five preclinical calcitonin gene-related peptide (CGRP) inhibitor assets.
The deal fulfills Pfizer's promise to investors to expand its late-stage and commercial portfolio with near-term growth drivers and puts...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?